INDP is trading 5.6% down at $3.22 as the market reacts to Indaptus Therapeutics halting a clinical trial and filing for a significant share resale.
- The company has paused enrollment in its ongoing cancer trial, creating clinical uncertainty and weighing on investor sentiment.
- A filing to resell 18.864 million shares tied to a $12 million private placement has increased the outstanding share supply and dilution risks.
- Today's decline reverses momentum from the previous session, where the stock had gained 4.6%.